MAPT and Alzheimer disease: For this purpose, we measured plasma NTA-tau levels in two large cohorts including cross-sectional and longitudinal samples of individuals across the AD continuum, healthy controls and nonAD cases, all well-characterized by clinically validated CSF and imaging biomarkers.